ARTICLE | Clinical News
CytomX begins Phase I/II of CX-2009 in solid tumors
July 3, 2017 7:07 PM UTC
CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC (CX-2009) in about 150 patients with metastatic or locally advanced unresectable solid tumors. The trial will recruit patients with non-small cell lung cancer (NSCLC), breast cancer, ovarian cancer, endometrial cancer, cholangiocarcinoma, head and neck cancer and castration-resistant prostate cancer.
The trial’s primary endpoint will evaluate dose-limiting toxicities (DLTs). Its secondary endpoints are objective response rate (ORR) and pharmacokinetics...
BCIQ Company Profiles
BCIQ Target Profiles